相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Peroxisome proliferator-activated receptor-γ antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines
Jack D. Burton et al.
ANTI-CANCER DRUGS (2007)
PPARγ inhibitors reduce tubulin protein levels by a PPARγ, PPARδ and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells
Katherine L. Schaefer et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Peroxisome proliferator-activated receptor-γ antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia
M Collin et al.
CRITICAL CARE MEDICINE (2006)
Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties
Hirokazu Takahashi et al.
CANCER SCIENCE (2006)
Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, reduces acute lung injury in endotoxemic rats
D Liu et al.
CRITICAL CARE MEDICINE (2005)
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ
G Pascual et al.
NATURE (2005)
Critical role of peroxisome proliferator-activated receptor γ on anoikis and invasion of squamous cell carcinoma
T Masuda et al.
CLINICAL CANCER RESEARCH (2005)
Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells
KL Schaefer et al.
CANCER RESEARCH (2005)
Transcriptional inactivation of STAT3 by PPARγ suppresses IL-6-responsive multiple myeloma cells
LH Wang et al.
IMMUNITY (2004)
CD74 is expressed by multiple myeloma and is a promising target for therapy
JD Burton et al.
CLINICAL CANCER RESEARCH (2004)
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies
R Stein et al.
BLOOD (2004)
GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation
JM Seargent et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Curcurnin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells
AC Bharti et al.
JOURNAL OF IMMUNOLOGY (2003)
A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity antidiabetic activity
J Rieusset et al.
MOLECULAR ENDOCRINOLOGY (2002)
Bisphenol A diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor-γ, in caspase-dependent and -independent manners
S Fehlberg et al.
BIOCHEMICAL JOURNAL (2002)
Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis
MA Frassanito et al.
BLOOD (2001)
Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators
Y Kodera et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Bisphenol A diglycidyl ether (BADGE) is a PPARγ agonist in an ECV304 cell line
D Bishop-Bailey et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
E Mueller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation
HM Wright et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
